Source: FDA, National Drug Code (US) Revision Year: 2020
Lovenox is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. The pH of the injection is 5.5 to 7.5.
Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. Its structure is characterized by a 2-O-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine at the reducing end of the chain. About 20% (ranging between 15% and 25%) of the enoxaparin structure contains a 1,6 anhydro derivative on the reducing end of the polysaccharide chain. The drug substance is the sodium salt. The average molecular weight is about 4500 daltons.
The molecular weight distribution is:
<2000 daltons | ≤20% |
2000 to 8000 daltons | ≥68% |
>8000 daltons | ≤18% |
STRUCTURAL FORMULA:
R1 = H or SO3Na and R2 = SO3 Na or COCH3
R | X* = 15 to 25% | n=0 to 20 | |
100-X | H | n=1 to 21 |
* X = Percent of polysaccharide chain containing 1,6 anhydro derivative on the reducing end
Lovenox 100 mg/mL Concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.
Lovenox 150 mg/mL Concentration contains 15 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.
The Lovenox prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection. The multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative [see Dosage and Administration (2) and How Supplied/Storage and Handling (16)].
Dosage Forms and Strengths | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Lovenox is a clear, colorless to pale-yellow solution available in two concentrations.
|
How Supplied | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lovenox is available in two concentrations (see Tables 26 and 27). Table 26. 100 mg/mL Concentration:
* Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox 30 and 4 0 mg prefilled syringes, and 60, 80, and 100 mg graduated prefilled syringes each contain 10 mg enoxaparin sodium per 0.1 mL Water for Injection. Table 27. 150 mg/mL Concentration:
* Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox 120 and 150 mg graduated prefilled syringes contain 15 mg enoxaparin sodium per 0.1 mL Water for Injection. sanofi-aventis U.S. LLC, Bridgewater, NJ 08807,A SANOFI COMPANY |
Drug | Countries | |
---|---|---|
LOVENOX | Austria, Canada, Germany, France, Tunisia, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.